Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

NCT04106219

Active Not RecruitingPhase 1

Sponsor: Eli Lilly and Company

Conditions: Neuroblastoma

Interventions: LY3295668 Erbumine, Topotecan, Cyclophosphamide

Countries: United States, Australia, Belgium, France, Germany, Italy, Japan, Spain

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

Eligibility overview

Sex: ALL

Age: 2 Years to 21 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue.
* Participants must be able to swallow capsules.

Exclusion Criteria:

* Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant.
* Participants must not have untreated tumor that has spread to the brain or spinal cord.
* Participants must not have a serious active disease other than neuroblastoma.
* Participants must not have a condition affecting absorption.
* Participants must not have had prior aurora kinase inhibitor exposure.
* Participants must not have a known allergy to the study treatment.
* Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
Locations (17)
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • Cincinnati, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Houston, Texas, United States
  • Perth, Western Australia, Australia
  • Ghent, Oost-Vlaanderen, Belgium
  • Lyon, Auvergne-Rhône-Alpes, France
  • Paris, France
  • Cologne, Germany
  • Milan, Lombardy, Italy
  • Chuo-ku, Tokyo, Japan
  • Barcelona, Barcelona [Barcelona], Spain
  • Madrid, Spain
  • Liverpool, United Kingdom